Form 4: Disc Medicine Director Granted 20,000 Stock Options

Disc Medicine, Inc. Director Nadim Ahmed was granted 20,000 stock options with an exercise price of $57.74, vesting over three years.

Summary

• Nadim Ahmed, a Director of Disc Medicine, Inc. (IRON), was granted 20,000 stock options.
• The options have an exercise price of $57.74 per share.
• The grant date for these options was July 14, 2025.
• The options expire on July 13, 2035.
• The shares underlying the option vest over three years: one-third on July 14, 2026, and the remaining two-thirds in substantially equal monthly installments over the subsequent two years.

Sentiment

Score: 6

Explanation: Slightly positive as it represents a standard practice for aligning director incentives with shareholder interests, indicating commitment and a long-term view, with minimal immediate negative impact.

Positives

• The stock option grant aligns the director's interests with long-term shareholder value creation.
• Provides an incentive for the director to contribute to the company's growth and performance.

Negatives

• Potential future dilution if the options are exercised, increasing the number of outstanding shares.

Risks

• The value of the stock options is dependent on the future market price of Disc Medicine's common stock exceeding the exercise price of $57.74.
• If the stock price does not increase above the exercise price, the options may not be exercised, limiting their incentive value.

Future Outlook

The vesting schedule of the stock options indicates a long-term incentive structure for the director, aligning their future compensation with the company's performance over the next three years.

Industry Context

This is a standard practice in the biotechnology and pharmaceutical industries to incentivize directors and executives through equity compensation, aligning their interests with long-term company performance and shareholder value.

Related Party Transactions

• The grant of 20,000 stock options to Nadim Ahmed, a Director of Disc Medicine, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the director's incentives lead to improved company performance; potential for minor dilution upon option exercise.
• Employees: No direct impact mentioned, but aligns with broader company compensation strategies.

Next Steps

• The vesting of the stock options will occur in stages, with the first one-third vesting on July 14, 2026.
• The remaining two-thirds will vest in substantially equal monthly installments over the two years following July 14, 2026.

Key Dates

Keywords

Disc Medicine, IRON, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Vesting Schedule